# Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

> **NCT01420809** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1280 (actual)

## Conditions studied

- Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01420809
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-05
- **Final completion:** 2009-08
- **Target enrollment:** 1280 (ACTUAL)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420809, "Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01420809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*